Nga viti 2030 do t\u00eb mund t’i themi lamtumir\u00eb protezave dhe implanteve. P\u00ebr t\u00eb pasur dh\u00ebmb\u00eb t\u00eb p\u00ebrsosur do t\u00eb mjaftoj\u00eb vet\u00ebm nj\u00eb injeksion p\u00ebr t\u00eb v\u00ebn\u00eb dh\u00ebmb\u00ebt. Ky \u00ebsht\u00eb premtimi i kompanis\u00eb japoneze Toregem Biopharma. Start-up i Universitetit t\u00eb Kiotos, i themeluar 4 vjet m\u00eb par\u00eb, po krijon nj\u00eb ila\u00e7 antitrupash i p\u00ebrshkruar si “i pari n\u00eb bot\u00eb p\u00ebr rilindjen e dh\u00ebmb\u00ebve” dhe do t\u00eb filloj\u00eb testimin e tij te njer\u00ebzit nga shtatori, pas rezultateve pozitive t\u00eb marra te kafsh\u00ebt. Q\u00ebllimi i studiuesve \u00ebsht\u00eb q\u00eb n\u00eb vitin 2030 t\u00eb jet\u00eb nj\u00eb sh\u00ebrbim p\u00ebr t\u00eb gjith\u00eb pacient\u00ebt q\u00eb duan t\u00eb aplikojn\u00eb k\u00ebt\u00eb risi. Sa kushton ky trajtim i ri?<\/p>\n
Toregem planifikon t\u00eb ofroj\u00eb k\u00ebt\u00eb trajtim t\u00eb ri p\u00ebr 9 mij\u00eb euro.<\/p>\n
Faza e par\u00eb e prov\u00ebs klinike do t\u00eb zgjas\u00eb nga shtatori 2024 deri n\u00eb gusht 2025. Terapia funksionon duke \u00e7aktivizuar nj\u00eb protein\u00eb t\u00eb quajtur Usag-1, e cila pengon rritjen e dh\u00ebmb\u00ebve dhe n\u00eb faz\u00ebn 1 t\u00eb provave njer\u00ebzore do t\u00eb administrohet n\u00eb m\u00ebnyr\u00eb intravenoze tek 30 t\u00eb rritur t\u00eb sh\u00ebndetsh\u00ebm t\u00eb mosh\u00ebs midis 30 dhe 64 vje\u00e7. Kushti p\u00ebr t\u00eb marr\u00eb pjes\u00eb n\u00eb k\u00ebt\u00eb trajtim n\u00eb baza eksperimentale \u00ebsht\u00eb mungesa e t\u00eb pakt\u00ebn nj\u00eb dh\u00ebmbi t\u00eb pasm\u00eb.<\/p>\n
Pasi t\u00eb jet\u00eb konfirmuar siguria e k\u00ebtij ila\u00e7i, do t\u00eb kalojm\u00eb n\u00eb faz\u00ebn tjet\u00ebr me administrimin e f\u00ebmij\u00ebve t\u00eb mosh\u00ebs 2 deri n\u00eb 7 vje\u00e7, t\u00eb cil\u00ebve u mungojn\u00eb t\u00eb pakt\u00ebn 4 dh\u00ebmb\u00eb q\u00eb nga lindja. Shpresa e studiuesve \u00ebsht\u00eb q\u00eb n\u00eb t\u00eb ardhmen t\u00eb jen\u00eb n\u00eb gjendje t\u00eb \u201crrisin dh\u00ebmb\u00ebt jo vet\u00ebm tek njer\u00ebzit me patologji t\u00eb lindura, por edhe tek ata q\u00eb i kan\u00eb humbur p\u00ebr shkak t\u00eb l\u00ebndimeve\u201d.<\/p>\n
Presidentja e Toregem Biopharma, start-upit japonez q\u00eb po zhvillon antitrupat, \u00ebsht\u00eb Honoka Kiso dhe ajo q\u00eb e lidh at\u00eb me k\u00ebt\u00eb risi n\u00eb mjek\u00ebsi \u00ebsht\u00eb nj\u00eb p\u00ebrvoj\u00eb personale q\u00eb ajo ndan n\u00eb faqen e internetit t\u00eb kompanis\u00eb:<\/p>\n
“Kur isha n\u00eb shkoll\u00eb t\u00eb mesme – thot\u00eb ajo – Kam humbur 2 dh\u00ebmb\u00eb p\u00ebr shkak t\u00eb nj\u00eb problem n\u00eb nofull dhe iu n\u00ebnshtrova nj\u00eb operacioni q\u00eb m\u00eb frym\u00ebzoi t\u00eb b\u00ebhesha dentist. Kur shkova n\u00eb universitet iu n\u00ebnshtrova nj\u00eb implanti dentar. Por doja t\u00eb studioja shkakun e s\u00ebmundjes sime dhe t\u00eb kuptoja se si t\u00eb rigjeneroja dh\u00ebmb\u00ebt e humbur, k\u00ebshtu q\u00eb ndoqa shkoll\u00ebn pasuniversitare n\u00eb 2008 dhe mora pjes\u00eb n\u00eb k\u00ebrkimin e Dr. Takahashi i cili nisi eksperimentin te minjt\u00eb p\u00ebr t\u00eb v\u00ebzhguar efektivitetin e trajtimit.<\/p>\n","protected":false},"excerpt":{"rendered":"
Nga viti 2030 do t\u00eb mund t’i themi lamtumir\u00eb protezave dhe implanteve. P\u00ebr t\u00eb pasur dh\u00ebmb\u00eb t\u00eb p\u00ebrsosur do t\u00eb mjaftoj\u00eb vet\u00ebm nj\u00eb injeksion p\u00ebr t\u00eb v\u00ebn\u00eb dh\u00ebmb\u00ebt. Ky \u00ebsht\u00eb premtimi i kompanis\u00eb japoneze Toregem Biopharma. Start-up i Universitetit t\u00eb Kiotos, i themeluar 4 vjet m\u00eb par\u00eb, po krijon nj\u00eb ila\u00e7 antitrupash i p\u00ebrshkruar si<\/p>\n","protected":false},"author":1,"featured_media":7620,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-7619","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-lifestyle"},"_links":{"self":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/7619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/comments?post=7619"}],"version-history":[{"count":1,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/7619\/revisions"}],"predecessor-version":[{"id":7621,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/7619\/revisions\/7621"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media\/7620"}],"wp:attachment":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media?parent=7619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/categories?post=7619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/tags?post=7619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}